Innate Pharma Announced That The First Patient Was Dosed In A Sanofi-sponsored Phase 1/2 Trial, Evaluating SAR'514 / IPH6401 In Relapsed/Refractory Multiple Myeloma And Relapsed/Refractory Light-chain Amyloidosis
Portfolio Pulse from Benzinga Newsdesk
Innate Pharma (IPHA) announced that the first patient has been dosed in a Sanofi (SNY)-sponsored Phase 1/2 trial. The trial is evaluating SAR'514 / IPH6401 in relapsed/refractory multiple myeloma and relapsed/refractory light-chain amyloidosis.
July 11, 2023 | 9:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Innate Pharma's drug SAR'514 / IPH6401 is being evaluated in a Sanofi-sponsored trial. This could potentially lead to positive outcomes for the company if the trial is successful.
The initiation of a clinical trial is generally seen as a positive development for a biotech company. If the trial is successful, it could lead to regulatory approval and potential revenue for Innate Pharma.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Sanofi is sponsoring a trial evaluating Innate Pharma's drug SAR'514 / IPH6401. This indicates Sanofi's interest in the potential of this drug.
Sanofi's sponsorship of this trial indicates their interest in the drug's potential. If the trial is successful, it could lead to a partnership or acquisition, which could be beneficial for Sanofi.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70